CEE321 / Novartis - LARVOL DELTA

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. (PubMed, J Med Chem) - "The JAK kinases JAK1, JAK2, JAK3, and TYK2 play key roles in cytokine signaling. Therefore, we consider CEE321 to be a "soft drug". When applied topically to human skin that was stimulated with the cytokines IL4 and IL13 ex vivo, CEE321 potently inhibited biomarkers relevant to atopic dermatitis."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL4 • JAK1 • JAK2 • JAK3 • TYK2

"$NVS discontinues pan-Jak CEE321 (ph1 for atopic dermatitis) over unfavourable risk/benefit. Earlier story via @ByAmyBrown & @ByLizC https://t.co/q1sMueYfJb" (@JacobPlieth)

Benefit-risk assessment • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A First-in-Human Study of CEE321 in Adult Subjects (clinicaltrials.gov) - P1; N=28; Completed; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A First-in-Human Study of CEE321 in Adult Subjects (clinicaltrials.gov) - P1; N=28; Recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Newly added product (Novartis) - Preclinical, Atopic Dermatitis

Pipeline update